What is the recommended antiplatelet therapy regimen after an acute ischemic stroke or high‑risk transient ischemic attack?

Antiplatelet Therapy After Acute Ischemic Stroke or High-Risk TIA

For minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), initiate dual antiplatelet therapy (DAPT) with aspirin 160-325 mg loading dose plus clopidogrel 300-600 mg loading dose within 12-24 hours of symptom onset, continue with aspirin 81 mg daily plus clopidogrel 75 mg daily for 21 days, then switch to single antiplatelet therapy indefinitely. 1

Acute Phase Management (First 24-48 Hours)

For Minor Stroke (NIHSS ≤3) or High-Risk TIA (ABCD2 ≥4)

Start DAPT immediately after excluding intracranial hemorrhage on neuroimaging:

• Loading doses: Aspirin 160-325 mg + Clopidogrel 300 mg (CHANCE trial dose) or 600 mg (POINT trial dose) 1
• Maintenance: Aspirin 81 mg daily + Clopidogrel 75 mg daily for 21 days 1
• Timing: Ideally within 12-24 hours of symptom onset 2, 1
• After 21 days: Switch to single antiplatelet therapy (aspirin 81 mg daily OR clopidogrel 75 mg daily) indefinitely 1

Alternative DAPT regimen for mild-moderate stroke (NIHSS ≤5):

• Aspirin 300-325 mg loading + Ticagrelor 180 mg loading
• Continue aspirin 75-100 mg daily + Ticagrelor 90 mg twice daily for 30 days
• Then switch to single antiplatelet therapy 1

For All Other Acute Ischemic Strokes (Not Minor)

Single antiplatelet therapy only:

• Aspirin 160 mg loading dose within 24-48 hours after excluding hemorrhage 1, 3
• Continue aspirin 81-325 mg daily indefinitely 1
• Do NOT use DAPT - increased bleeding risk without proven benefit in moderate-severe strokes 2

Critical Timing Considerations

DAPT works ONLY when started early:

• The benefit of DAPT is time-dependent - efficacy demonstrated only when initiated within 24 hours (ideally 12 hours) 2, 4
• Starting DAPT beyond 72 hours has not been adequately studied and may not provide the same benefit 4
• The INSPIRES trial showed benefit even when started within 72 hours, but effect size may be smaller 4

Long-Term Secondary Prevention (After Acute Phase)

Choose ONE of the following single antiplatelet agents:

• Aspirin 81-325 mg daily, OR
• Clopidogrel 75 mg daily, OR
• Aspirin 25 mg + Extended-release dipyridamole 200 mg twice daily 1, 3

Preferred agents over aspirin alone:

• Clopidogrel is slightly more effective than aspirin for preventing vascular events 3
• Aspirin-dipyridamole combination is also superior to aspirin alone 3

Special Populations and Contraindications

Patients Who Cannot Swallow

• Rectal aspirin 325 mg daily, OR
• Aspirin 81 mg daily via enteral tube, OR
• Clopidogrel 75 mg daily via enteral tube 1

Post-Thrombolysis Patients

Delay antiplatelet therapy for 24 hours:

• Wait until 24-hour post-thrombolysis scan excludes intracranial hemorrhage before starting any antiplatelet therapy 2
• This applies to both single and dual antiplatelet regimens

Intracranial Atherosclerotic Stenosis (50-99%)

DAPT is appropriate medical therapy:

• Standard DAPT regimen as above for acute phase
• Angioplasty and stenting NOT recommended 1

Cardioembolic Stroke with Atrial Fibrillation

Do NOT use antiplatelet therapy:

• Oral anticoagulation is indicated, not antiplatelet agents 3
• If anticoagulation contraindicated, then consider aspirin 325 mg daily 5

Critical Pitfalls to Avoid

1. Do NOT extend DAPT beyond 21-30 days:

• The MATCH trial showed that prolonged DAPT (beyond 90 days) significantly increases major bleeding risk (1.3% absolute increase in life-threatening bleeding) without additional benefit 6, 7
• The POINT trial confirmed increased major hemorrhage with 90-day DAPT (0.9% vs 0.4%, HR 2.32) 2

2. Do NOT use DAPT for moderate-severe strokes:

• No evidence of benefit in NIHSS >3
• Increased hemorrhagic transformation risk 2

3. Do NOT combine aspirin + clopidogrel long-term:

• Only indicated for 21-30 days acutely
• Long-term combination increases bleeding without reducing stroke recurrence 6

4. Do NOT give aspirin within 24 hours of thrombolysis:

• Wait for 24-hour post-treatment imaging to exclude hemorrhage 2, 8

Evidence Strength and Nuances

The recommendation for short-term DAPT is based on two high-quality trials:

• CHANCE trial (Chinese population): 8.2% vs 11.7% stroke recurrence with DAPT vs aspirin alone (HR 0.68) 2
• POINT trial (predominantly US population): 4.6% vs 6.3% ischemic stroke with DAPT vs aspirin alone (HR 0.72) 2

Key insight: For every 1000 patients treated with DAPT for 90 days, 15 ischemic strokes are prevented but 5 major hemorrhages occur 2. This is why the duration is limited to 21-30 days - to maximize benefit while minimizing bleeding risk.

The 2023 World Stroke Organization guidelines 1 and 2018 Canadian guidelines 2 represent the most current, high-quality evidence and should guide practice. Older guidelines from 2006-2012 5, 3, 8, 6 predate the CHANCE and POINT trials and do not reflect current best practice for acute minor stroke/high-risk TIA.